Last reviewed · How we verify
R2-MANT
R2-MANT is a mantle cell lymphoma-directed immunotherapy combining rituximab with a novel antitumor mechanism in phase 3 development.
R2-MANT is a mantle cell lymphoma-directed immunotherapy combining rituximab with a novel antitumor mechanism in phase 3 development. Used for Mantle cell lymphoma.
At a glance
| Generic name | R2-MANT |
|---|---|
| Also known as | Rituximab and Lenalidomide (R2) |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Target | CD20 (presumed, based on rituximab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R2-MANT appears to be an investigational combination or novel formulation approach for mantle cell lymphoma (MCL), likely leveraging rituximab (anti-CD20) as a backbone. The specific mechanistic innovation of the 'MANT' component is not publicly well-characterized in standard pharmaceutical databases, suggesting it may be a proprietary or recently disclosed regimen by Fondazione Italiana Linfomi.
Approved indications
- Mantle cell lymphoma
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R2-MANT CI brief — competitive landscape report
- R2-MANT updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI